The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

In a report released on January 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €182.00. The company’s shares ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab, marketed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...